Auna Announces 2Q26 Financial Results
A consecutive quarter of strong top-line growth and cash flow performance;
Consolidated Adjusted EBITDA impacted by service mix across the segments
LUXEMBOURG, August 18, 2026--Auna (NYSE: AUNA) ("Auna" or the "Company"), a leading healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, announced today financial results for the second quarter ended June 30, 2026 ("Second quarter 2026" or "2Q26"). Financial results are expressed in Peruvian Soles ("S/" or "PEN" or "Soles") and are presented in accordance with International Financial Reporting Standards ("IFRS"), unless otherwise noted.
2Q'26 Consolidated Highlights
Revenue increased 9% FXN, or 13% YoY on a reported basis, to S/1,238 million
Adjusted EBITDA was S/227 million, a decrease of 9% YoY FXN or 6% YoY on a reported basis, and an increase of 3% FXN from 1Q26
Adjusted EBITDA Margin of 18.4%, slightly up from 1Q26
Operating Cash Flow and Free Cash Flow increased 45% YoY and 181% YoY, respectively
Leverage Ratio improved to 3.6x
Oncology MLR remained stable at 50.1%
Number of surgeries increased 5.2% YoY to 21,912
Number of days hospitalized increased 5% YoY to 135,107
Number of chemotherapy and radiotherapy sessions increased 15% YoY
Message from Auna's Executive Chairman and President
The second quarter of 2026 demonstrated sustained commercial momentum across our markets and progress in the operational initiatives that support our growth strategy. Revenue increased by 9% FXN, while Adjusted EBITDA declined 9% FXN. This reflects service mix and temporary margin pressure in Mexico and Colombia, as well as pharmacy and payroll costs, along with the impact of accepted penalties primarily related to billing matters in the reconciliation of prior years' receivables in Peru.
In Peru, our integrated model continues to deliver strong results, Peru achieved an 8% revenue growth, driven by new B2B memberships at Oncosalud and increased volumes in high-complexity procedures within our healthcare network. Oncosalud expanded its B2B membership base, while higher occupancy in the healthcare network underscored our focus on growing in high complexity. Adjusted EBITDA reflects increased pharmacy, physician and payroll expenses required to accommodate the surge in patient volumes, as well as accepted penalties primarily attributable to previous years' billing matters.
In Mexico, patient volume recovery continued throughout the quarter. Improved tier classifications with key payors, improved pricing for high-complexity services, and the ongoing expansion of our oncology offering contributed to stronger volumes, particularly in June. This momentum drove 4% year-over-year revenue growth in local currency, while revenue and Adjusted EBITDA increased by 5% and 3%, respectively, compared to the first quarter of 2026, in local currency. Although service mix and talent investments continued to affect margins year over year, both Adjusted EBITDA and margin improved sequentially, indicating progress in the initiatives underway in Monterrey and positioning the network for sustained volume growth in the second half.